ESR1 and ductal breast carcinoma in situ: The PROMISE study is a window of opportunity trial comparing the change in breast tissue proliferation and estrogen-responsive genes with 4 weeks of BZA/CE compared to placebo in women with ER-positive ductal carcinoma in situ (ClinicalTrials.gov NCT02694809).